Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma

Lenvatinib is an oral multikinase inhibitor approved for use as first‐line treatment for patients with advanced hepatocellular carcinoma (HCC). However, like other agents in this drug class, lenvatinib is associated with clinically important adverse events (AEs) that could adversely affect patient o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bo Hyun, Yu, Su Jong, Kang, Wonseok, Cho, Sung Bum, Park, Soo Young, Kim, Seung Up, Kim, Do Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299126/
https://www.ncbi.nlm.nih.gov/pubmed/34725855
http://dx.doi.org/10.1111/jgh.15727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299126/
https://www.ncbi.nlm.nih.gov/pubmed/34725855
http://dx.doi.org/10.1111/jgh.15727

Ejemplares similares